Immix Biopharma
Stock Forecast, Prediction & Price Target
Immix Biopharma Financial Estimates
Immix Biopharma Revenue Estimates
Immix Biopharma EBITDA Estimates
Immix Biopharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $-89.51M 0% | $0 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $12.14M Low: $12.14M High: $12.14M avg. 0% | Avg: $48.15M Low: $48.15M High: $48.15M avg. 296.63% | Avg: $109.87M Low: $109.87M High: $109.87M avg. 128.16% |
Net Income
% change YoY
| $-24.38M N/A | $-8.22M 66.24% | $-15.42M -87.44% | Avg: $-26.59M Low: $-17.51M High: $-17.51M avg. -72.39% | Avg: $-10.10M Low: $-6.41M High: $-6.41M avg. 62.01% | Avg: $14.39M Low: $14.39M High: $14.39M avg. 242.49% | Avg: $47.34M Low: $47.34M High: $47.34M avg. 228.91% |
EBITDA
% change YoY
| $-1.34M N/A | $-8.21M -508.85% | $-16.13M -96.37% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $9.93M Low: $9.93M High: $9.93M avg. 0% | Avg: $39.40M Low: $39.40M High: $39.40M avg. 296.63% | Avg: $89.91M Low: $89.91M High: $89.91M avg. 128.16% |
EPS
% change YoY
| -$1.84 N/A | -$0.62 66.30% | -$0.89 -43.54% | Avg: -$1.01 Low: -$1.01 High: -$1.01 avg. -13.48% | Avg: -$0.37 Low: -$0.37 High: -$0.37 avg. 63.36% | Avg: $0.83 Low: $0.83 High: $0.83 avg. 324.32% | Avg: $2.73 Low: $2.73 High: $2.73 avg. 228.91% |
Operating Expenses
% change YoY
| $1.35M N/A | $8.21M 507.90% | $16.14M 96.38% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $9.60M Low: $9.60M High: $9.60M avg. 0% | Avg: $38.09M Low: $38.09M High: $38.09M avg. 296.63% | Avg: $86.91M Low: $86.91M High: $86.91M avg. 128.16% |
FAQ
What is Immix Biopharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 115.25% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -17.51M, average is -26.59M and high is -17.51M.
What is Immix Biopharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 106.19% in 2025-2028.
We have gathered data from 1 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Immix Biopharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 150.78% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$1.01, average is -$1.01 and high is $-1.01.
What is the best performing analyst?
In the last twelve months analysts have been covering Immix Biopharma stock. The most successful analyst is Robert Burns.